For each included study, data was extracted on study design, baseline population characteristics, intervention details (type and dose of GLP-1 receptor agonists), comparator, mean follow-up duration and reported cardiovascular outcomes
Drugs that will address those are going to be the clear winners in the next 4 to 5 years. For years, GLP-1 medicines have come as weekly injectables
Additionally, tirzepatide is not recommended for patients with severe gastrointestinal disease, including severe gastroparesis
Can you lose rapid weight with Semaglutide GLP-1
The Phase 3 TRIUMPH-4 trial showed an average loss of 71.2 pounds, with additional benefits for osteoarthritis relief
That combination can be especially appealing to patients who want a structured path forward rather than trying to figure everything out on their own